Ann: Percheron to launch Share Purchase Plan, page-18

well let’s see…

I think there is the growing realisation. The European Medicines Agency has always been much more sceptical on this point than FDA. It’s a good time to be developing an anti-inflammatory drug.
We wait



“But the results could also pose a much broader problem, STAT’s Jason Mast and Adam Feuerstein write. The Food and Drug Administration approved Sarepta Therapeutics’ Duchenne therapy on the basis of a belief that increasing microdystrophin levels were a sign the treatment was effective. Companies including RegenxBio and Solid Biosciences are developing their own treatments on this basis.“The point is not only the level of expression of microdystrophin, but how functional it is,” the head of a gene therapy nonprofit told STAT. “A probable conclusion from these data is that this particular microdystrophin is not as efficient in humans as [Pfizer] had expected”